Cost-effectiveness analysis of mecapegfilgrastim and recombinant human granulocyte stimulating factor for primary prophylaxis of chemotherapy-induced neutropenia in non-small cell lung cancer
Int. Journal of Clinical Pharmacology and Therapeutics · 2024
DOI: 10.5414/cp204479 ↗Kurz gefasst
Fachartikel in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, 2024. Verfasst von Yong-Li Gu und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neutropenia, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Gu, Y. L., Sun, Z. X., Sun, Y., Guan, X., & Jiang, D. L. (2024). Cost-effectiveness analysis of mecapegfilgrastim and recombinant human granulocyte stimulating factor for primary prophylaxis of chemotherapy-induced neutropenia in non-small cell lung cancer. Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cp204479
Vancouver
Gu YL, Sun ZX, Sun Y, Guan X, Jiang DL. Cost-effectiveness analysis of mecapegfilgrastim and recombinant human granulocyte stimulating factor for primary prophylaxis of chemotherapy-induced neutropenia in non-small cell lung cancer. Int. Journal of Clinical Pharmacology and Therapeutics. 2024. doi:10.5414/cp204479
BibTeX
@article{Gu2024,
author = {Gu, Yong-Li and Sun, Zeng-Xian and Sun, Ying and Guan, Xin and Jiang, Dao-Li},
title = {Cost-effectiveness analysis of mecapegfilgrastim and recombinant human granulocyte stimulating factor for primary prophylaxis of chemotherapy-induced neutropenia in non-small cell lung cancer},
journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
year = {2024},
doi = {10.5414/cp204479}
}
EUVIMED